Key result
SMILE chemotherapy improves myocardial function in an ENKL case despite fatal lymphoma progression within ~2 months.
Why the study?
Extranodal natural killer/T-cell lymphoma, nasal type with myocardial involvement and severe heart failure is rare and its clinical course and treatment outcomes are not well described.
Case Report (n=1)
No
SMILE chemotherapy may improve myocardial function in patients with ENKL and myocardial involvement, despite the overall poor prognosis.
May support SMILE for myocardial recovery in rare ENKL cases; hypothesis-generating and requires prospective validation.
We report a rare case of exteranodal natural killer (NK)/T-cell lymphoma, nasal type (ENKL) with myocardial involvement and severe heart failure. A 50-year-old Japanese woman who presented with nasal obstruction feel and palpitation on exertion was introduced to our hospital. Computed tomography (CT) imaging showed a mass in the right nasopharynx. Echocardiography confirmed left ventricular hypertrophy and a moderate pericardial effusion without tamponade physiology. As the patient’s left ventricular ejection fraction was depressed at 30%, heart failure was therefore diagnosed. Biopsy of the right nasopharyngeal mass revealed pathologic features diagnostic ENKL. Endomyocardial biopsy from the left ventricular posterior wall demonstrated myocardial involvement of ENKL.The patient received 3 cycle of systemic chemotherapy including of steroids, methotrexate, ifosfamide, L-aspaginase, and etoposide (SMILE). Myocardial function was improved with treatment of SMILE, but she died from progressive lymphoma within 2 months of completing 3 cycle of chemotherapy. Although, prognosis remains poor in disseminated ENKLs, the clinical course of the patient suggests that SMILE regimen is worth trying for ENKL patients with myocardial involvement.
No takes yet. Share an insight, caveat, or question.
Kosugi et al. (2018) conducted a case report in Extranodal natural killer/T-cell lymphoma, nasal type (ENKL) with myocardial involvement and severe heart failure (n=1). SMILE chemotherapy (steroids, methotrexate, ifosfamide, L-aspaginase, and etoposide) was evaluated on Myocardial function and survival. SMILE chemotherapy improved myocardial function in a patient with ENKL and myocardial involvement, although she died from progressive lymphoma within 2 months of completing 3 cycles.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: